An open Label, Prospective , Comparative, Multiple Arm Pilot Study toCompare and Evaluate the Adverse Events Profile of Cancer PatientsUndergoing Conventional Treatment Patterns of Chemotherapy andAdding N- 163 and AFO 202 as Adjunct Therapy to ConventionalTreatment

ichiIn Biosciences Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1. Aged 18 to 65.
•2. Patients who diagnosed with breast cancer.
•3. Patients who are on 1st and 2nd cycles of chemotherapy.
•4. Diagnostic histopathology of Breast Cancer stage II and above.
•5. Subjects with any co-morbid conditions can be added.
•6. Patient who are willing into participate in the study with a written Informed Consent. Form.

•1. Have previously received any cancer therapy including but not limited to radiotherapy, chemotherapy and surgery.
•2. Use of GCSF-Granulokine Â® (growth-stimulating factor granulocyte).
•3. Use of immunosuppressive drugs, diuretics and supplements of zinc or copper.
•4. Use of other supplements during the study duration.
•5. Significant cardiac, pulmonary, renal, hepatic, gastrointestinal, CNS, psychiatric disease or illicit substance use/abuse that in the opinion of the investigator would make the participant a poor candidate for study participation.
•6. Patients with a history of autoimmune or inflammatory disease, active infectious disease, liver disease or renal failure.
•7. Pregnancy (for women of childbearing potential)/lactation.
•8. Systemic use of progestinâ??s, androgens or other steroids -dexamethasone is allowed if used as antiemetic therapy.

发起方

ichiIn Biosciences Pvt Ltd